NCT00702364

Efficacy Study of Strattera for Treating Attention Disorders in Traumatic Brain Injury (TBI)

Strattera(Atomoxetine) for the Treatment of Attention Disorders in Individuals With Traumatic Brain Injury

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 60 (actual)
• Sponsor: Craig Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Atomoxetine is the only medication that is currently approved by the FDA for the treatment of attention deficit hyperactivity disorder in adults. It has gained recent interest as an alternative medication for treating attentional problems related to traumatic brain injury (TBI), but it's effectiveness in this population has not been studied. There are a number of advantages of Atomoxetine over traditional neuro-stimulant medications currently used for attentional disorders after traumatic brain injury. This study will use a randomized double-blind placebo-controlled crossover design to investigate the efficacy of atomoxetine to improve attention, behavioral function, and depression in adults with TBI

Conditions

• Traumatic Brain INjury

Interventions

Type	Name	Description
DRUG	atomoxetine
DRUG	placebo

Timeline

• Start date: 2008-01-01
• Primary completion: 2012-03-01
• Completion: 2012-03-01
• First posted: 2008-06-20
• Last updated: 2014-09-15
• Results posted: 2014-09-15

Locations

1 site across 1 country: United States